Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octreotide for refractory anemia due to gastrointestinal bleeding from small bowel angiodysplasias
2014-004032-19Phase 3Completed
- Sponsor
- Radboud University Medical Center
- Start
- Sep 2015
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of octreotide in Small bowel angiodysplasia (SBA) and refractory anemia (RA) (2 arms), sponsored by Radboud University Medical Center. Started Sep 2015; status: completed.
02
Drugs
octreotide
03
Conditions
Small bowel angiodysplasia (SBA)refractory anemia (RA)
Beyond the preview
Go deeper on 2014-004032-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004032-19.